47 related articles for article (PubMed ID: 21176752)
1. Efficacy and safety of daptomycin in patients with renal impairment: a multicenter retrospective analysis.
Kullar R; McClellan I; Geriak M; Sakoulas G
Pharmacotherapy; 2014 Jun; 34(6):582-9. PubMed ID: 24658897
[TBL] [Abstract][Full Text] [Related]
2. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.
Haselden M; Leach M; Bohm N
Ann Pharmacother; 2013 Oct; 47(10):1342-7. PubMed ID: 24259698
[TBL] [Abstract][Full Text] [Related]
3. Safety of daptomycin in patients receiving hemodialysis.
Mueller BA; Crompton JA; Donovan BJ; Yankalev S; Lamp KC
Pharmacotherapy; 2011 Jul; 31(7):665-72. PubMed ID: 21923453
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD.
Khadzhynov D; Slowinski T; Lieker I; Spies C; Puhlmann B; König T; Uhrig A; Eggers K; Neumayer HH; Traunmüller F; Joukhadar C; Peters H
Int J Clin Pharmacol Ther; 2011 Nov; 49(11):656-65. PubMed ID: 22011690
[TBL] [Abstract][Full Text] [Related]
5. Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
Chuk AC; Saeed F; Kousar N; Burrill S; Barns B; Rickrode G; Fu J; Katrych O; Saunders-Hao P; Block C; Lahey T
Clin Nephrol; 2015 Oct; 84(4):214-21. PubMed ID: 26308080
[TBL] [Abstract][Full Text] [Related]
6. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis.
Patel N; Cardone K; Grabe DW; Meola S; Hoy C; Manley H; Drusano GL; Lodise TP
Antimicrob Agents Chemother; 2011 Apr; 55(4):1677-83. PubMed ID: 21282429
[TBL] [Abstract][Full Text] [Related]
7. Removal of common antimicrobial agents by sustained low-efficiency dialysis.
Hudson JQ; Hilgers MN; Gosmanova EO
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0157923. PubMed ID: 38349160
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation.
Lewis SJ; Jang SM; Mueller BA
BMC Nephrol; 2023 Sep; 24(1):270. PubMed ID: 37710245
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin Pharmacokinetics in Adolescents Undergoing Hemodialysis and Peritoneal Dialysis: A Case Series With Pharmacokinetic Modeling.
Lim SY; Lewis T; Woo S; Turman M; Bourne DWA; Burton ME; Rianthavorn P
J Pediatr Pharmacol Ther; 2021; 26(2):123-132. PubMed ID: 33603575
[TBL] [Abstract][Full Text] [Related]
10. Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.
Cimino C; Burnett Y; Vyas N; Norris AH
Drugs; 2021 Apr; 81(5):555-574. PubMed ID: 33591549
[TBL] [Abstract][Full Text] [Related]
11. Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.
Ma TK; Leung CB; Chow KM; Kwan BC; Li PK; Szeto CC
Clin Kidney J; 2016 Aug; 9(4):616-23. PubMed ID: 27478608
[TBL] [Abstract][Full Text] [Related]
12. Daptomycin pharmacokinetics and pharmacodynamics in a pooled sample of patients receiving thrice-weekly hemodialysis.
Butterfield JM; Mueller BA; Patel N; Cardone KE; Grabe DW; Salama NN; Lodise TP
Antimicrob Agents Chemother; 2013 Feb; 57(2):864-72. PubMed ID: 23208714
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of multiple doses of daptomycin 6 mg/kg in noninfected adults undergoing hemodialysis or continuous ambulatory peritoneal dialysis.
Benziger DP; Pertel PE; Donovan J; Yankelev S; Schwab RJ; Swan SK; Cannon C
Clin Nephrol; 2011 Jan; 75(1):63-9. PubMed ID: 21176752
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.
Cardone KE; Lodise TP; Patel N; Hoy CD; Meola S; Manley HJ; Drusano GL; Grabe DW
Clin J Am Soc Nephrol; 2011 May; 6(5):1081-8. PubMed ID: 21393490
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.
Vilay AM; Grio M; Depestel DD; Sowinski KM; Gao L; Heung M; Salama NN; Mueller BA
Crit Care Med; 2011 Jan; 39(1):19-25. PubMed ID: 20890189
[TBL] [Abstract][Full Text] [Related]
16. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections.
Abdel-Rahman SM; Chandorkar G; Akins RL; Bradley JS; Jacobs RF; Donovan J; Benziger DP
Pediatr Infect Dis J; 2011 Aug; 30(8):712-4. PubMed ID: 21317681
[TBL] [Abstract][Full Text] [Related]
17. [Safety of daptomycin in patients with renal impairment].
Azanza JR; Quetglas EG
Med Clin (Barc); 2010 Dec; 135 Suppl 3():55-9. PubMed ID: 21477705
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
